SCHEDULE 13G/A: BlackRock Discloses 8.2% Passive Stake in Intellia Therapeutics

BlackRock, Inc. has filed an updated Schedule 13G, revealing a passive beneficial ownership of 8.2% of Intellia Therapeutics, Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 8,453,014 shares of Intellia Therapeutics, Inc. common stock.
• This represents 8.2% of the total outstanding common stock of Intellia Therapeutics, Inc.
• BlackRock holds sole voting power over 8,272,147 shares and sole dispositive power over 8,453,014 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a routine update by a passive investor.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• BlackRock, Inc. operates under Rule 13d-1(b), signifying its status as a passive institutional investor.
• Various BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are involved in the beneficial ownership, with at least one entity owning 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing indicating a significant, passive institutional investment. It doesn't contain positive or negative news about the issuer's operations, but the presence of a large, stable investor like BlackRock can be seen as a mild positive for market confidence.

Positives

• BlackRock's significant 8.2% stake indicates a substantial institutional investment in Intellia Therapeutics, potentially signaling confidence from a major asset manager.
• The filing confirms BlackRock's passive investment intent, which can provide stability by reducing concerns about activist interventions.

Negatives

• The document does not contain any negative information regarding Intellia Therapeutics, as it is a disclosure of ownership by an institutional investor.

Risks

• The document does not explicitly mention risks related to Intellia Therapeutics, as its primary purpose is to disclose beneficial ownership by BlackRock.

Future Outlook

The Schedule 13G filing does not contain any forward-looking statements or guidance regarding Intellia Therapeutics, Inc.'s future performance or BlackRock's investment strategy beyond its passive intent.

Management Comments

• The filing includes a certification from BlackRock, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Intellia Therapeutics, Inc.

Industry Context

This filing is a routine disclosure by BlackRock, one of the world's largest asset managers, indicating its passive investment in a biotechnology company. Such large institutional holdings are common across various industries and reflect a fund manager's portfolio allocation decisions rather than specific operational insights into the issuer. Intellia Therapeutics operates in the biotechnology sector, focusing on gene editing, an area that attracts significant institutional investment due to its long-term growth potential.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily details an institutional investor's stake and does not provide operational or financial results for direct comparison to industry standards.
• However, BlackRock's 8.2% passive stake in Intellia Therapeutics is a significant holding for a single institutional investor, aligning with typical large fund allocations in promising biotechnology companies.
• For instance, other major asset managers like Vanguard or State Street often hold similar or larger passive stakes in publicly traded companies as part of their index or passively managed funds.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by BlackRock may provide a degree of stability and confidence, as it indicates a major institutional investor's long-term, non-activist interest in the company.
• Employees, Customers, Suppliers, Creditors: This filing has no direct impact on these stakeholders, as it pertains solely to an institutional ownership stake and not the company's operations, financial health, or strategic direction.

Next Steps

• The document does not specify any future actions, events, or milestones for Intellia Therapeutics or BlackRock beyond the ongoing regulatory reporting requirements for beneficial ownership.

Key Dates

Keywords

BlackRock, Intellia Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, NTLA, Asset Management